Draft guidance on abemaciclib as first endocrine-based therapy in breast cancer

  • National Institute for Health and Care Excellence

  • curated by Dawn O'Shea
  • Medical news
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

NICE has issued draft guidance recommending abemaciclib with an aromatase inhibitor as first endocrine-based therapy for previously untreated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer.

The recommendation is based on data from the double blind, placebo-controlled, randomised MONARCH 3 trial comparing abemaciclib with placebo (both taken with letrozole or anastrozole). Interim results showed that median progression-free survival (PFS) was not reached for abemaciclib and was 19.2 months for placebo (HR 0.51; 95% CI 0.36-0.72). The final progression-free survival analysis was presented to the committee, but the results are confidential until publication.

The overall-survival (OS) data from MONARCH 3 are immature. At the interim analysis, OS was similar between the treatment groups (9.8% with abemaciclib and 10.3% with placebo).

Network meta-analyses carried out by the company compared abemaciclib with palbociclib and ribociclib (each with an aromatase inhibitor). Analyses included PFS, OS, and a number of response rates analyses, but networks were not possible for adverse events, treatment duration, and quality of life. The results of the meta-analysis are confidential but the NICE appraisal committee said similar treatment effects were shown for all 3 cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors.

“Taking into account the commercial arrangements for all cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors, abemaciclib is a cost-effective use of NHS resources and it can be recommended,” the guidance states.

A final decision is due from NICE later this month.